Hyperfine (HYPR) Capital Expenditures Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Capital Expenditures Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 27.22% |
| 10 | Hyperfine | 155.82 Mn | 114.55 Mn | 1.98 Mn | -94.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.50% |
| Dec 31, 2025 | 106.93% |
| Sep 30, 2025 | -150.94% |
| Jun 30, 2025 | 19.58% |
| Mar 31, 2025 | -31.40% |
| Dec 31, 2024 | -245.35% |
| Sep 30, 2024 | -69.31% |
| Jun 30, 2024 | -6,475.00% |
| Mar 31, 2024 | 1,961.11% |
| Dec 31, 2023 | 63.29% |
| Sep 30, 2023 | 199.42% |
| Jun 30, 2023 | 85.19% |
| Mar 31, 2023 | -88.31% |
| Dec 31, 2022 | -83.79% |
| Sep 30, 2022 | -83.69% |
| Jun 30, 2022 | -110.69% |
| Mar 31, 2022 | 81.18% |